LIPOCALIN MUTEIN DRY POWDER FORMULATION FOR TREATMENT OF ASTHMA
The present invention relates to the treatment of asthma in a human subject by administering by oral inhalation a dry powder formulation comprising a therapeutically effective amount of an anti-IL-4 receptor alpha (IL-4Ra) lipocalin mutein, or a variant or fragment thereof, to said subject. The inve...
Saved in:
Main Authors | , , , , , , |
---|---|
Format | Patent |
Language | English Spanish |
Published |
29.09.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present invention relates to the treatment of asthma in a human subject by administering by oral inhalation a dry powder formulation comprising a therapeutically effective amount of an anti-IL-4 receptor alpha (IL-4Ra) lipocalin mutein, or a variant or fragment thereof, to said subject. The invention also relates to the dry powder formulation comprising the anti-IL-4 receptor alpha (IL-4Ra) lipocalin mutein, or a variant or fragment thereof.
La presente invención está relacionada con el tratamiento del asma en un sujeto humano mediante la administración por inhalación oral de una formulación de polvo seco que comprende una cantidad con eficacia terapéutica de una muteína de lipocalina contra el receptor alfa de IL-4 (IL-4Ra), o una variante o fragmento de esta, a dicho sujeto. La invención también está relacionada con la formulación de polvo seco que comprende la muteína de lipocalina contra el receptor alfa de IL-4 (IL-4Ra), o una variante o un fragmento de esta. |
---|---|
Bibliography: | Application Number: CR20230000265 |